Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963381 | 1.00 | GSK3B (0.40) | GSK3BS1PR1HTTPKMPIK3R1 | |
| SCHEMBL1963380 | 1.00 | GSK3B (0.40) | GSK3BS1PR1HTTPKMPIK3R1 | |
| SCHEMBL4870979 | 0.85 | GSK3B (0.51) | GSK3BPIK3R1PIK3CAROCK2MAP4K4 | |
| SCHEMBL4870985 | 0.85 | GSK3B (0.51) | GSK3BPIK3R1PIK3CAROCK2MAP4K4 | |
| SCHEMBL4870991 | 0.85 | GSK3B (0.51) | GSK3BPIK3R1PIK3CAROCK2MAP4K4 | |
| Hydrochloric Acid SCHEMBL4872469 | 0.84 | GSK3B (0.50) | GSK3BPIK3R1PIK3CAROCK2MAP4K4 | |
| Hydrochloric Acid SCHEMBL4872474 | 0.84 | GSK3B (0.50) | GSK3BPIK3R1PIK3CAROCK2MAP4K4 | |
| Hydrochloric Acid SCHEMBL4872464 | 0.84 | GSK3B (0.50) | GSK3BPIK3R1PIK3CAROCK2MAP4K4 | |
| SCHEMBL1842262 | 0.82 | GSK3B (0.39) | GSK3BHTTPKMTSHRLMNA | |
| SCHEMBL4870920 | 0.81 | GSK3B (0.37) | GSK3BPKMPIK3R1PIK3CATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592580-B2 | Substituted triazinone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | claimed |
| EP-2321295-B1 | 4-(PYRIDIN-4-YL)-1H-[1,3,5]TRIAZIN-2-ONE DERIVATIVES AS GSK3-BETA INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-12-21 | — | — | EP | claimed |
| US-20110144114-A1 | SUBSTITUTED TRIAZINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2138488-A1 | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases | sanofi-aventis (FR) | 2009-12-30 | — | — | EP | claimed |
| US-8592580-B2 | Substituted triazinone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2321295-B1 | 4-(PYRIDIN-4-YL)-1H-[1,3,5]TRIAZIN-2-ONE DERIVATIVES AS GSK3-BETA INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110144114-A1 | SUBSTITUTED TRIAZINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2138488-A1 | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases | sanofi-aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144114-A1 | SUBSTITUTED TRIAZINONE DERIVATIVES | TBXA2R, ARG2, GLS | GSK3B 1923/4885S1PR1 556/4885HTT 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.